Skip to content
DataLookout
Menu

NCT01937468

Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

StatusActive, Not Recruiting
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 27 versions: 17 with changes below, 10 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 31 words Show 5 more changesShow less
    • Study completion pushed from Dec 2026 to Dec 2027
    • Secondary endpoints: details revised at 1 of 3 entries
    • Site details revised at 1 of 2 sites
    • Publications: details revised at 1 of 1 entry
    • Study description expanded, about 2 words
  2. Minor Study completion date: Dec 2025 to Dec 2026v26
  3. Minor Study completion date: Dec 2024 to Dec 2025v24
  4. Minor Collaborators revised (3)v23
  5. Minor Study completion date: Dec 2023 to Dec 2024v21
Show 11 earlier versionsHide 11 earlier versions
  1. Minor Study completion date: Dec 2021 to Dec 2023v19
  2. Minor Study completion date: Dec 2020 to Dec 2021v17
  3. Minor Collaborators revised (3)v16
  4. Minor Study completion date: Nov 2020 to Dec 2020
    • Collaborators revised (3)
    v15
  5. Minor Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Nov 2018 to Aug 2017
    • Site details revised at 2 of 2 sites
    v11
  6. Notable Primary completion date: Nov 2016 to Nov 2018
    • Study completion date: Jul 2018 to Nov 2020
    v10
  7. Notable Eligibility criteria shortened, about 7 wordsv8
  8. Notable Trial status: Suspended to Recruiting
    • Site details revised at 2 of 2 sites
    v7
  9. Stopped Trial status: Recruiting to Suspended Sponsor's reason: IL-2 supply shortage
    • Site details revised at 2 of 2 sites
    v6
  10. Notable Eligibility criteria expanded, about 7 wordsv4
  11. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 2013 to Nov 2013
    • Site details revised at 2 of 2 sites
    v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Adverse event profile and the maximum tolerate dose of Treg-enriched infusion plus 8-week low-dose IL-2
Timeframe: 24 weeks post Treg infusion, with continued follow-up for participants on extended duration IL-2 therapy.

Secondary (3)

To determine feasibility of Treg-enriched infusion plus 8-week low-dose IL-2
Clinical response of cGVHD as defined by the NIH consensus criteria to Treg-enriched infusion plus 8-week low-dose IL-2
Expansion of Treg cells in the peripheral blood after a Treg-enriched infusion plus 8-week low-dose IL-2

Arms and interventions

Treg-enriched infusion plus 8-week low-dose Interleukin-2Experimental

Treg-enriched Cell Dose: Participants will be targeted to a defined dose of donor Treg-enriched total nucleated cells. Initial enrollment will be at target dose-level A. Subsequent cohorts will be dose escalated/de-escalated per the schema. Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).

Other: Treg-enriched infusion

Drugs: Interleukin-2

Sites

2 sites in 1 country